• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • MRI Images
  • Sample Access
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

EPAD presented at the AD/PD conference

2019-03-26News

The 14th​ International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2019) and related neurological disorders took place in Lisbon (Portugal) from 26-31 March. It provided a world class platform for international clinical investigators and scientists to present, discuss and trade expertise on a broad range of themes and topics. The event attracted over 3,800 participants from over 70 countries.

The conference started on 26 March with three pre-conference workshops:

  • Common features of neurodegenerative diseases: exploring the brain-eye connection and beyond
  • Basic neuropathology of age-associated neurodegenerative disease
  • The promise and pitfalls of Real-World-Evidence in Alzheimer’s disease.

The scientific director of the Alzheimer’s Prevention Program of the Barcelonaβeta Brain Research Center (BBRC), Dr José Luis Molinuevo, was invited to give a talk at the preconference meeting and asked to present  the European Prevention of Alzheimer’s Dementia (EPAD) project and the Amyloid Imaging to Prevent Alzheimer’s Disease (AMYPAD) project. He participated in a session about Key Real-World-Evidence initiatives in Alzheimer’s disease chaired by Colin Masters.

In his talk, Dr Molinuevo gave an overview of the EPAD project. He started by introducing the EPAD project, its consortium and objectives. He further explained the Longitudinal Cohort Study (LCS) and highlighted the number of European participating countries. By end March 2019, there were 21 study sites up and running, with more than 1,500 research participants recruited. He also mentioned the data collected within the study and ended with the main achievements of the EPAD project.

Then, Dr Molinuevo presented the AMYPAD project aiming to improve the understanding, diagnosis and management of Alzheimer’s disease through the utilisation of ß-amyloid PET imaging. He mentioned the AMYPAD consortium which is a combination of 9 academic partners, 3 industrial partners, 2 SMEs and 1 patient organisation. He explained the Diagnostic and Patient Management Study (DMPS) and the Prognostic and Natural History Study (PNHS) including their objectives, design and current status. As per 29 March 2019, the DMPS is performed in Geneva, Amsterdam, Toulouse, Cologne, Barcelona and London with 244 patients spread on the active sites. The PNHS has three active sites (Amsterdam, Edinburgh, and Barcelona) with 86 research participants.

Share this post
FacebookTwitterLinkedInGoogle+
Related posts
Edinburgh Dementia Prevention Summer School 2022
2022-06-30
EPAD at AAIC22!
2022-06-30
ADDI NeuroToolKit Data Hackathon
2022-05-17
The Neuronet Coordination and Support Action releases updated Decision Tool for engagement with Regulatory and Health Technology Assessment bodies
2022-05-09
First national follow-on study to EPAD LCS launches
2022-04-07
The EPAD genomic data is now available on the Alzheimer’s Disease Workbench
2022-03-10
Latest News
  • Edinburgh Dementia Prevention Summer School 2022
    2022-06-30
  • EPAD at AAIC22!
    2022-06-30
  • ADDI NeuroToolKit Data Hackathon
    2022-05-17
  • The Neuronet Coordination and Support Action releases updated Decision Tool for engagement with Regulatory and Health Technology Assessment bodies
    2022-05-09
  • First national follow-on study to EPAD LCS launches
    2022-04-07
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

The @AlzData #NeuroToolKit Data Hackathon has started! 45 teams are uing the NTKApp, @IMI_EPAD datasets, and statistical analysis tools available on the #ADWorkbench to investigate the potential clinical utility of different biomarkers in #Alzheimer’s disease. twitter.com/AlzData/status…

reply retweet favorite
10:34 am · 2022-07-04
Twitter
EPAD
EPAD
@IMI_EPAD

The @CenDemPrevent Summer School, a 4-day interactive course on #brainhealth, is designed for clinicians, researchers and students. Space is limited, sign up quickly! 🗓️26-29 September 📍Edinburgh For more info, including programme⤵️ ep-ad.org/edinburgh-deme… pic.twitter.com/FSypbvWK4L

reply retweet favorite
12:38 pm · 2022-06-30
Twitter
EPAD
EPAD
@IMI_EPAD

There’s still time to join the @AlzData #NeuroToolKit #Data Hackathon! Registration closes on 24 June! Participants will work with @IMI_EPAD datasets and utilise the tools on the #ADWorkbench. Interested in participating? ➡️alzheimersdata.org/hackathon twitter.com/IMI_EPAD/statu…

reply retweet favorite
7:21 am · 2022-06-22
Twitter
EPAD
EPAD
@IMI_EPAD

Today, colleagues from @AlzData visited @CenDemPrevent to meet with those involved in various programmes including @IMI_EPAD @AD_PREVENT. Many relevant discussions and great catch-up! #BrainHealth #datasharing #collaboration @craig_ritchie68 @samdansobe @GregorySarah @CindyBirck pic.twitter.com/Mr3trKeuoz

reply retweet favorite
2:43 pm · 2022-06-15
Twitter
EPAD
EPAD
@IMI_EPAD

Have a look on the new @AlzheimerEurope #DementiaInEurope magazine featuring an article on @IMI_EPAD and its collaboration with @AlzData to make our data findable, accessible and reusable. @craig_ritchie68 ⤵️ alzheimer-europe.org/resource… twitter.com/AlzheimerEurop… pic.twitter.com/vLuW3HMLUh

reply retweet favorite
1:09 pm · 2022-06-14
Copyright © 2015-2021 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT